Evidence map›Paper›PMID 32813078›Full record

ReviewHandbook of experimental pharmacology2021

Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO•) and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation.

Barbara K Kemp-Harper, Anida Velagic, Nazareno Paolocci, John D Horowitz, Rebecca H Ritchie

Abstract readReview
PubMed Publisher
In one paragraph

Review in Handbook of experimental pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Kinetic Study on the Reactivity of Azanone (HNO) toward CyclicInternational journal of molecular sciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Barbara K Kemp-HarperDepartment of Pharmacology, Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia. barbara.kemp@monash.edu.
Anida VelagicBaker Heart & Diabetes Institute, Melbourne, VIC, Australia.
Nazareno PaolocciDivision of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
John D HorowitzBasil Hetzel Institute, Queen Elizabeth Hospital, University of Adelaide, Adelaide, SA, Australia.
Rebecca H RitchieDepartment of Pharmacology, Cardiovascular Disease Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
Monash University · AUAustralian Regenerative Medicine Institute · AUJohns Hopkins University · USQueen Elizabeth Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive oxygen species (ROS) dysregulation is a hallmark of cardiovascular disease, characterised by an imbalance in the synthesis and removal of ROS. ROS such as superoxide (•O

Indexed as

Nitric OxideSiblingsHumansHydrogen PeroxideNitrogen OxidesOxidation-ReductionReactive Oxygen SpeciesHydrogen PeroxideNitric OxideNitrogen OxidesnitroxylReactive Oxygen SpeciesCardiovascularNitric oxideNitroxylReactive oxygen species

Identifiers

PMID32813078
OpenAlexW3054417943

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.